Background
Methods
Data source
Study population
Study variables
Statistical analysis
Results
Patient characteristics
No-chemo | 5FU/Capecitabine | FOLFOX/CapeOX | |
---|---|---|---|
Gender | |||
Male | 3124 | 3591 | 799 |
Female | 5645 | 4467 | 865 |
Age at diagnosis, years | |||
66–70 | 554 | 1826 | 584 |
71–75 | 1002 | 2422 | 514 |
76–80 | 1784 | 2180 | 419 |
> 80 | 5429 | 1630 | 147 |
Race | |||
White | 7369 | 6909 | 1407 |
Black | 841 | 592 | 132 |
Asian | 244 | 260 | 52 |
Other | 315 | 297 | 73 |
Marital status | |||
Single+Separated | 823 | 551 | 125 |
Married | 3105 | 4620 | 1044 |
Divorced+Widowed | 4535 | 2654 | 443 |
Other | 306 | 233 | 52 |
Residence location | |||
Big Metro | 4802 | 4219 | 878 |
Metro or Urban | 2963 | 2853 | 588 |
Less Urban or Rural | 1002 | 986 | 198 |
Median household income | |||
1st quartile | 2203 | 1803 | 371 |
2nd quartile | 2102 | 1976 | 375 |
3rd quartile | 2062 | 1949 | 393 |
4th quartile | 2035 | 2029 | 443 |
Unknown | 367 | 301 | 82 |
Level of education | |||
1st quartile | 2064 | 2003 | 401 |
2nd quartile | 2029 | 2015 | 373 |
3rd quartile | 2136 | 1920 | 400 |
4th quartile | 2173 | 1819 | 408 |
Unknown | 367 | 301 | 82 |
Year of diagnosis | |||
1992–1996 | 1837 | 1902 | 0 |
1997–2000 | 1678 | 1887 | 0 |
2001–2004 | 2739 | 3169 | 240 |
2005–2008 | 2515 | 1100 | 1424 |
Primary tumor site | |||
right-sided colon | 5867 | 5111 | 1068 |
left-sided colon | 2730 | 2809 | 572 |
unknown | 172 | 138 | 24 |
Histologic grade | |||
Well | 432 | 422 | 99 |
Moderate | 5360 | 5169 | 1046 |
Poor+Undifferentiated | 2756 | 2251 | 486 |
Unknown | 221 | 216 | 33 |
Histologic type | |||
Adenocarcinoma | 7402 | 6811 | 1425 |
Mucinous carcinoma | 1216 | 1140 | 212 |
Signet-ring cell carcinoma | 151 | 107 | 27 |
pT category | |||
pT1 | 173 | 302 | 69 |
pT2 | 571 | 721 | 150 |
pT3 | 6185 | 5805 | 1223 |
pT4a | 1040 | 861 | 150 |
pT4b | 800 | 369 | 72 |
pN category | |||
pN1a | 3315 | 2898 | 500 |
pN1b | 2889 | 2750 | 554 |
pN2a | 1550 | 1518 | 357 |
pN2b | 1015 | 892 | 253 |
pTNM stage | |||
pTNM IIIa | 673 | 920 | 190 |
pTNM IIIb | 6239 | 5814 | 1132 |
pTNM IIIc | 1857 | 1324 | 342 |
Preoperative intestinal obstruction | |||
No | 6406 | 6648 | 1367 |
Yes | 2363 | 1410 | 297 |
Preoperative intestinal perforation | |||
No | 8576 | 7998 | 1648 |
Yes | 193 | 60 | 16 |
HCC risk score | |||
1st quartile | 2557 | 1811 | 289 |
2nd quartile | 1685 | 2427 | 539 |
3rd quartile | 1972 | 2195 | 492 |
4th quartile | 2555 | 1625 | 344 |
Number of examined lymph node | |||
≥ 12 | 4674 | 4274 | 1213 |
< 12 | 4095 | 3784 | 451 |
Postoperative radiotherapy | |||
No | 8692 | 7765 | 1639 |
Yes | 77 | 293 | 25 |
Timing to AC | |||
≤ 4 weeks | 0 | 660 | 86 |
5–8 weeks | 0 | 5118 | 1047 |
9–12 weeks | 0 | 1502 | 381 |
13–16 weeks | 0 | 369 | 97 |
≥ 17 weeks | 0 | 409 | 53 |
No-chemo | 8769 | 0 | 0 |
Overall comparison of the timing of chemotherapy
Variables | Univariate analysis | Multivariate analysis* | ||||
---|---|---|---|---|---|---|
HR | 95% CI |
P
| HR | 95% CI |
P
| |
Gender | 0.136 | |||||
Male | 1 | |||||
Female | 0.952 | 0.893–1.015 | ||||
Age at diagnosis, years | < 0.001 | < 0.001 | ||||
66–70 | 1 | 1 | ||||
71–75 | 1.157 | 1.054–1.269 | 1.133 | 1.030–1.245 | ||
76–80 | 1.359 | 1.238–1.492 | 1.330 | 1.209–1.463 | ||
> 80 | 1.929 | 1.752–2.123 | 1.834 | 1.657–2.029 | ||
Race | < 0.001 | 0.001 | ||||
White | 1 | 1 | ||||
Black | 1.039 | 0.922–1.171 | 0.980 | 0.864–1.112 | ||
Asian | 0.625 | 0.503–0.777 | 0.636 | 0.511–0.793 | ||
Other | 0.989 | 0.836–1.169 | 0.961 | 0.811–1.139 | ||
Marital status | < 0.001 | 0.011 | ||||
Single+Separated | 1 | 1 | ||||
Married | 0.818 | 0.723–.926 | 0.856 | 0.755–0.970 | ||
Divorced+Widowed | 0.994 | 0.874–1.129 | 0.948 | 0.833–1.079 | ||
Other | 0.838 | 0.670–1.047 | 0.905 | 0.723–1.133 | ||
Residence location | 0.222 | |||||
Big Metro | 1 | |||||
Metro or Urban | 0.942 | 0.878–1.010 | ||||
Less Urban or Rural | 0.996 | 0.901–1.102 | ||||
Median household income | 0.023 | 0.872 | ||||
1st quartile | 1 | 1 | ||||
2nd quartile | 0.993 | 0.906–1.088 | 1.042 | 0.943–1.152 | ||
3rd quartile | 0.926 | 0.843–1.016 | 1.000 | 0.895–1.119 | ||
4th quartile | 0.872 | 0.795–0.957 | 1.013 | 0.893–1.15 | ||
Unknown | 0.945 | 0.795–1.123 | 1.056 | 0.860–1.298 | ||
Level of education | < 0.001 | 0.001 | ||||
1st quartile | 1 | 1 | ||||
2nd quartile | 1.164 | 1.061–1.278 | 1.154 | 1.045–1.274 | ||
3rd quartile | 1.159 | 1.055–1.272 | 1.142 | 1.022–1.276 | ||
4th quartile | 1.262 | 1.149–1.385 | 1.286 | 1.130–1.463 | ||
Unknown | 1.142 | 0.960–1.358 | N/Aa | N/Aa | ||
Year of diagnosis | < 0.001 | < 0.001 | ||||
1992–1996 | 1 | 1 | ||||
1997–2000 | 0.863 | 0.784–0.950 | 0.833 | 0.756–0.918 | ||
2001–2004 | 0.814 | 0.748–0.885 | 0.754 | 0.692–0.822 | ||
2005–2008 | 0.667 | 0.605–0.737 | 0.609 | 0.549–0.675 | ||
Primary tumor site | < 0.001 | 0.006 | ||||
right-sided colon | 1 | 1 | ||||
left-sided colon | 0.822 | 0.767–0.880 | 0.891 | 0.829–0.957 | ||
unknown | 1.241 | 0.988–1.559 | 1.034 | 0.821–1.302 | ||
Histologic grade | < 0.001 | < 0.001 | ||||
Well | 1 | 1 | ||||
Moderate | 1.156 | 0.987–1.353 | 1.073 | 0.915–1.257 | ||
Poor+Undifferentiated | 1.748 | 1.487–2.055 | 1.384 | 1.174–1.630 | ||
Unknown | 1.274 | 0.991–1.638 | 1.120 | 0.869–1.445 | ||
Histologic type | < 0.001 | 0.101 | ||||
Adenocarcinoma | 1 | 1 | ||||
Mucinous carcinoma | 1.123 | 1.026–1.229 | 1.024 | 0.934–1.123 | ||
Signet-ring cell carcinoma | 1.893 | 1.503–2.384 | 1.289 | 1.019–1.632 | ||
pT category | < 0.001 | < 0.001 | ||||
pT1 | 1 | 1 | ||||
pT2 | 1.071 | 0.824–1.391 | 1.019 | 0.783–1.325 | ||
pT3 | 2.025 | 1.616–2.536 | 1.594 | 1.269–2.002 | ||
pT4a | 2.98 | 2.348–3.782 | 2.205 | 1.732–2.806 | ||
pT4b | 5.459 | 4.253–7.008 | 3.404 | 2.636–4.395 | ||
pN category | < 0.001 | < 0.001 | ||||
pN1a | 1 | 1 | ||||
pN1b | 1.374 | 1.263–1.495 | 1.305 | 1.199–1.420 | ||
pN2a | 1.844 | 1.682–2.021 | 1.675 | 1.526–1.838 | ||
pN2b | 3.215 | 2.920–3.541 | 2.874 | 2.595–3.183 | ||
Preoperative intestinal obstruction | < 0.001 | < 0.001 | ||||
No | 1 | 1 | ||||
Yes | 1.425 | 1.319–1.540 | 1.246 | 1.152–1.349 | ||
Preoperative intestinal perforation | < 0.001 | 0.001 | ||||
No | 1 | 1 | ||||
Yes | 2.284 | 1.723–3.028 | 1.628 | 1.223–2.168 | ||
HCC risk score | < 0.001 | < 0.001 | ||||
1st quartile | 1 | 1 | ||||
2nd quartile | 0.950 | 0.865–1.043 | 1.161 | 1.053–1.280 | ||
3rd quartile | 1.109 | 1.010–1.217 | 1.347 | 1.223–1.483 | ||
4th quartile | 1.447 | 1.315–1.593 | 1.644 | 1.489–1.815 | ||
Number of examined lymph node | 0.003 | < 0.001 | ||||
≥ 12 | 1 | 1 | ||||
< 12 | 1.102 | 1.034–1.175 | 1.295 | 1.209–1.387 | ||
Postoperative radiotherapy | < 0.001 | < 0.001 | ||||
No | 1 | 1 | ||||
Yes | 1.620 | 1.391–1.887 | 1.323 | 1.133–1.545 | ||
Timing to AC | < 0.001 | < 0.001 | ||||
≤ 4 weeks | 1 | 1 | ||||
5–8 weeks | 0.982 | 0.867–1.113 | 1.045 | 0.921–1.185 | ||
9–12 weeks | 1.169 | 1.019–1.341 | 1.222 | 1.063–1.405 | ||
13–16 weeks | 1.237 | 1.031–1.483 | 1.252 | 1.041–1.505 | ||
≥ 17 weeks | 2.207 | 1.870–2.604 | 1.969 | 1.663–2.331 |
Comparison of the timing of FOLFOX/CapeOX chemotherapy
Variables | Univariate analysis | Multivariate analysis* | ||||
---|---|---|---|---|---|---|
HR | 95% CI |
P
| HR | 95% CI |
P
| |
Gender | 0.092 | |||||
Male | 1 | |||||
Female | 0.845 | 0.695–1.028 | ||||
Age at diagnosis, years | 0.003 | 0.007 | ||||
66–70 | 1 | 1 | ||||
71–75 | 1.122 | 0.872–1.443 | 1.149 | 0.888–1.486 | ||
76–80 | 1.286 | 0.994–1.665 | 1.293 | 0.991–1.688 | ||
> 80 | 1.812 | 1.305–2.517 | 1.816 | 1.285–2.566 | ||
Race | 0.206 | |||||
White | 1 | |||||
Black | 1.028 | 0.719–1.469 | ||||
Asian | 1.156 | 0.677–1.972 | ||||
Other | 0.502 | 0.259–0.973 | ||||
Marital status | 0.167 | |||||
Single+Separated | 1 | |||||
Married | 1.036 | 0.696–1.543 | ||||
Divorced+Widowed | 1.318 | 0.869–1.999 | ||||
Other | 1.066 | 0.540–2.104 | ||||
Residence location | 0.329 | |||||
Big Metro | 1 | |||||
Metro or Urban | 1.071 | 0.865–1.327 | ||||
Less Urban or Rural | 1.252 | 0.929–1.686 | ||||
Median household income | 0.007 | 0.497 | ||||
1st quartile | 1 | 1 | ||||
2nd quartile | 0.962 | 0.733–1.261 | 1.021 | 0.755–1.380 | ||
3rd quartile | 0.745 | 0.561–0.989 | 0.814 | 0.575–1.152 | ||
4th quartile | 0.620 | 0.465–0.826 | 0.792 | 0.529–1.186 | ||
Unknown | 0.800 | 0.496–1.291 | 0.947 | 0.514–1.743 | ||
Level of education | 0.006 | 0.263 | ||||
1st quartile | 1 | 1 | ||||
2nd quartile | 1.524 | 1.117–2.079 | 1.371 | 0.979–1.920 | ||
3rd quartile | 1.552 | 1.147–2.100 | 1.379 | 0.960–1.982 | ||
4th quartile | 1.744 | 1.298–2.343 | 1.289 | 0.854–1.947 | ||
Unknown | 1.417 | 0.863–2.327 | N/Aa | N/Aa | ||
Year of diagnosis | 0.398 | |||||
2001–2004 | 1 | |||||
2005–2008 | 0. 897 | 0.697–1.154 | ||||
Primary tumor site | 0.150 | |||||
right-sided colon | 1 | |||||
left-sided colon | 0.878 | 0.711–1.084 | ||||
unknown | 1.602 | 0.824–3.114 | ||||
Histologic grade | < 0.001 | 0.022 | ||||
Well | 1 | 1 | ||||
Moderate | 1.170 | 0.724–1.892 | 1.015 | 0.623–1.653 | ||
Poor+Undifferentiated | 1.973 | 1.211–3.215 | 1.407 | 0.856–2.315 | ||
Unknown | 1.376 | 0.598–3.165 | 0.987 | 0.422–2.309 | ||
Histologic type | 0.008 | 0.148 | ||||
Adenocarcinoma | 1 | 1 | ||||
Mucinous carcinoma | 1.491 | 1.146–1.940 | 1.306 | 0.997–1.712 | ||
Signet-ring cell carcinoma | 1.467 | 0.728–2.959 | 1.147 | 0.556–2.366 | ||
pT category | < 0.001 | < 0.001 | ||||
pT1 | 1 | 1 | ||||
pT2 | 1.374 | 0.499–3.780 | 1.472 | 0.531–4.080 | ||
pT3 | 3.645 | 1.506–8.823 | 2.730 | 1.118–6.667 | ||
pT4a | 6.221 | 2.494–15.521 | 5.077 | 2.014–12.801 | ||
pT4b | 7.165 | 2.766–18.559 | 4.350 | 1.656–11.424 | ||
pN category | < 0.001 | < 0.001 | ||||
pN1a | 1 | 1 | ||||
pN1b | 1.581 | 1.172–2.132 | 1.475 | 1.090–1.996 | ||
pN2a | 2.301 | 1.691–3.132 | 1.970 | 1.440–2.696 | ||
pN2b | 4.310 | 3.195–5.814 | 3.408 | 2.497–4.650 | ||
Preoperative intestinal obstruction | < 0.001 | 0.055 | ||||
No | 1 | 1 | ||||
Yes | 1.680 | 1.340–2.106 | 1.258 | 0.995–1.590 | ||
Preoperative intestinal perforation | 0. 165 | |||||
No | 1 | |||||
Yes | 1.770 | 0.790–3.966 | ||||
HCC risk score | < 0.001 | < 0.001 | ||||
1st quartile | 1 | 1 | ||||
2nd quartile | 0.936 | 0.683–1.283 | 1.129 | 0.816–1.561 | ||
3rd quartile | 1.033 | 0.754–1.415 | 1.273 | 0.918–1.765 | ||
4th quartile | 1.994 | 1.469–2.705 | 2.197 | 1.592–3.033 | ||
Number of examined lymph node | 0.382 | |||||
≥ 12 | 1 | |||||
< 12 | 0.906 | 0.727–1.130 | ||||
Postoperative radiotherapy | 0.055 | |||||
No | 1 | |||||
Yes | 1.850 | 0.988–3.467 | ||||
Timing to AC | < 0.001 | < 0.001 | ||||
≤ 4 weeks | 1 | 1 | ||||
5–8 weeks | 1.028 | 0.635–1.663 | 1.009 | 0.619–1.644 | 0.971 | |
9–12 weeks | 1.665 | 1.012–2.739 | 1.640 | 0.990–2.717 | 0.055 | |
13–16 weeks | 1.671 | 0.935–2.988 | 1.422 | 0.788–2.566 | 0.243 | |
≥ 17 weeks | 3.144 | 1.731–5.710 | 2.482 | 1.354–4.549 | 0.003 |